MIT Scientists Identify Genetic Mechanism Behind Leaky Brain Blood Vessels in Rett Syndrome
Key Takeaways
- ▸Two distinct MECP2 mutations that cause Rett syndrome both trigger overexpression of miRNA-126-3p, identifying a common molecular mechanism across different genetic variants
- ▸The vascular defects result from reduced expression and mislocalization of ZO-1, a critical protein for maintaining tight seals between blood vessel cells
- ▸Reducing miRNA-126-3p levels can rescue vascular defects, suggesting a potential therapeutic target for treating Rett syndrome
Summary
MIT researchers have discovered how two common genetic mutations causing Rett syndrome compromise the structural integrity of developing brain blood vessels, making them leaky. The study, led by Tatsuya Osaki and senior author Mriganka Sur at MIT's Picower Institute for Learning and Memory, found that both mutations trigger overexpression of a microRNA called miRNA-126-3p, which disrupts the tight seals between blood vessel cells. The research used advanced human tissue cultures derived from induced pluripotent stem cells (iPS cells) from Rett syndrome patients to model vessel development and identify the molecular chain of events leading to vascular defects.
Rett syndrome is a severe developmental disorder that typically becomes apparent when affected children (mostly girls) reach 2-3 years of age—a critical period for brain blood vessel development. The study specifically examined two distinct MeCP2 gene mutations (R306C and R168X) and demonstrated that despite their different mechanisms, both ultimately lead to the same vascular problem through miRNA-126-3p overexpression. The researchers found that vessels with these mutations showed reduced expression of ZO-1, a key protein responsible for forming tight junctions between endothelial cells. Importantly, the team demonstrated that reducing miRNA-126-3p levels helped rescue the vascular defect, suggesting a potential therapeutic pathway.
- Advanced tissue engineering with 3D microvascular networks derived from patient cells enabled detailed mechanistic study of the disease
Editorial Opinion
This research represents a significant step forward in understanding Rett syndrome's neurological pathology by identifying a common molecular mechanism across genetically distinct mutations. By demonstrating that miRNA-126-3p overexpression serves as a downstream consequence of MeCP2 mutations and directly causes vascular dysfunction, the researchers have uncovered a promising therapeutic target. The use of patient-derived tissue models to validate interventions strengthens the translational potential of these findings, offering hope for developing treatments that could address the vascular component of this severe developmental disorder.
